First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

Table 1 Baseline characteristics of the patients [n = 81, n (%)]

Variables	Dexlansoprazole	Esomeprazole	P value
Age (mean ± SD, yr)	50.6 ± 13.3	49.9 ± 12.8	0.985
Male sex	34 (42.0)	43 (53.1)	0.137
Smoking	12 (14.8)	9 (11.1)	0.483
Alcohol use	22 (27.2)	22 (27.2)	1.000
Ingestion of coffee	44 (54.3)	36 (44.4)	0.209
Ingestion of tea	58 (71.6)	49 (60.5)	0.230
Betel nut	4 (4.9)	1 (1.2)	0.173
Spicy food	52 (64.2)	51 (63.0)	0.870
Sweet food	72 (88.9)	75 (92.6)	0.416
Body mass index	25.4 ± 4.8	24.9 ± 4.4	0.420
Waist girth	88.8 ± 12.2	88.7 ± 11.4	0.361
Metabolic syndrome	36 (44.4)	38 (46.9)	0.950
Atypical symptoms
Chest pain	38 (46.9)	39 (48.1)	0.588
Dysphagia	20 (24.7)	22 (27.2)	0.557
Regurgitation of food	29 (35.8)	31 (38.3)	0.561
Nausea	26 (32.1)	23 (28.4)	0.544
Hiccup	37 (45.7)	44 (54.3)	0.300
Foreign body sensation (throat)	48 (59.3)	40 (49.4)	0.301
Foreign body sensation (chest)	16 (19.8)	16 (19.8)	0.604
Hoarseness	28 (34.6)	28 (34.6)	0.604
Throat cleaning	44 (54.3)	44 (54.3)	0.602
Cough	38 (46.9)	34 (42.0)	0.516
Sore throat	20 (24.7)	20 (24.7)	0.604
Dry mouth	54 (66.7)	52 (64.2)	0.590
Bad breath	29 (35.8)	30 (37.0)	0.590
Epigastric pain	36 (44.4)	45 (55.6)	0.197
Epigastric fullness	65 (80.2)	54 (66.7)	0.111
Insomnia	36 (44.4)	28 (34.6)	0.199
Sinusitis	7 (8.6)	14 (17.3)	0.102
Otitis media	5 (6.2)	5 (6.2)	1.000
Sugar	97.4 ± 12.5	97.0 ± 12.8	0.604
Cholesterol	205.3 ± 36.7	207.7 ± 35.4	0.971
Triglyceride	121.9 ± 57.2	113.7 ± 64.7	0.284
HDL	54.7 ± 18.2	55.3 ± 14.4	0.866
LDL	127.0 ± 32.7	127.5 ± 32.8	0.942
H. pylori infection
Previous history - no	10 (12.3)	15 (18.5)	0.553
Current infection - no	10 (12.3)	12 (14.8)	0.703
Endoscopic findings
Hiatal hernia	10 (12.3)	15 (18.5)	0.347
GEFV (grade 3 or 4)	7 (8.6)	8 (9.9)	0.521
Esophagitis grade B	15 (18.5)	13 (16.0)	0.678

HDL: High-density lipoprotein; LDL: low-density lipoprotein; H. pylori: Helicobacter pylori; GEFV: Gastroesophageal flap valve.

Table 2 Comparison of the complete symptom resolution rates and night-time breakthrough heartburn between dexlansoprazole and esomeprazole over one week [n = 81, n (%)]

Variables	Dexlansoprazole	Esomeprazole	P value
CSR Day 1	21 (25.9)	23 (28.4)	0.724
CSR Day 3	27 (33.3)	26 (32.1)	0.867
CSR Day 7	42 (51.9)	39 (48.1)	0.637
Night reflux	45 (76.3)	40 (74.1)	0.787
Night heart burn	20 (33.9)	18 (33.3)	0.949
Night acid reflux	20 (33.9)	19 (35.2)	0.886
Frequency of night symptoms	2.7 ± 2.0	2.7 ± 2.4	0.343

CSR: Complete symptom resolution.

Table 3 Comparison of the complete symptom resolution rates between dexlansoprazole and esomeprazole over one week (Subgroup analysis by gender) n (%)

Time	Gender	Dexlansoprazole	Esomeprazole	P value
CSR Day 1	Female	13 (27.7)	6 (15.8)	0.192
	Male	8 (23.5)	17 (39.5)	0.136
CSR Day 3	Female	18 (38.3)	7 (18.4)	0.046
	Male	9 (26.5)	19 (44.2)	0.109
CSR Day 7	Female	26 (55.3)	14 (36.8)	0.090
	Male	16 (47.1)	25 (58.1)	0.333

CSR: Complete symptom resolution.

Table 4 Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week based on dexlansoprazole and esomeprazole administration

Time	PPI	Clinical factors	CSR	Coefficient of variation	Odds ratio (95%CI)	P value
Day 1	Dexlansoprazole	Null
	Esomeprazole	Female	15.80%	-1.249 ± 0.543	0.285 (0.103-0.789)	0.022
Day 3	Dexlansoprazole	Null
	Esomeprazole	Female	18.40%	-1.254 ± 0.519	0.287 (0.099-0.832)	0.016
Day 7	Dexlansoprazole	Null
	Esomeprazole	Null

CSR: Complete symptom resolution; PPI: Proton pump inhibitor.

Table 5 Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week

Time	Clinical factor	CSR	Coefficient of variation	Odds ratio (95%CI)	P value
Day 1	Spicy food	No: 37.3%	-0.969 ± 0.438	0.380 (0.161-0.896)	0.027
		Yes: 21.4%
Day 3	Null
Day 7	Null

CSR: Complete symptom resolution.